Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
No benefit found for doxorubicin/docetaxel vs. doxorubicin/cyclophosphamide
June 30th, 2005
Researchers in Scotland compared "the clinical and pathologic response rates of doxorubicin and cyclophosphamide (AC) with doxorubicin and docetaxel (AD) as primary chemotherapy in women with primary or locally advanced breast cancer." They found no benefit for one regimen over the other. "Eligible patients with histologically proven breast cancer with primary tumors {{>=}}3 cm, inflammatory or locally advanced disease, and no evidence of metastases were randomly assigned to receive a maximum of six cycles of either doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) administered intravenously (IV) every 3 weeks or...
Source: Women's Health Weekly (2005-06-30)
|
